Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Advanced Cancers and FGFR Genetic Alterations”

10 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 10 of 10 results

Testing effectiveness (Phase 2)Study completedNCT02272998
What this trial is testing

Ponatinib for Patients Whose Advanced Solid Tumor Cancer Has Activating Mutations Involving the Following Genes: FGFR1, FGFR2, FGFR3, FGFR4, RET, KIT.

Who this might be right for
Malignant Neoplasm
Sameek Roychowdhury 22
Testing effectiveness (Phase 2)Ended earlyNCT03827850
What this trial is testing

FGFR Inhibitor in FGFR Dysregulated Cancer

Who this might be right for
Lung CancerNSCLCPulmonary Neoplasm+2 more
Lung Cancer Group Cologne 22
Testing effectiveness (Phase 2)Ended earlyNCT02109016
What this trial is testing

Assess the Efficacy and Safety of the VEGFR-FGFR Inhibitor, Lucitanib, Given to Patients With Advanced/Metastatic Lung Cancer and FGF, VEGF, or PDGF Related Genetic Alterations

Who this might be right for
Non-Small Cell Lung CancerSquamous Non-Small Cell Lung CancerNSCLC+6 more
Clovis Oncology, Inc. 18
Testing effectiveness (Phase 2)Study completedNCT01752920
What this trial is testing

Phase 1/2 Study of Derazantinib (ARQ 087) in Adult Subjects With Advanced Solid Tumors With FGFR Genetic Alterations

Who this might be right for
Solid Tumor
Basilea Pharmaceutica 119
Testing effectiveness (Phase 2)Active Not RecruitingNCT06777316
What this trial is testing

An FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors

Who this might be right for
Intrahepatic Cholangiocarcinoma (Icc)CholangiocarcinomaOther Solid Tumors, Adult+9 more
Cogent Biosciences, Inc. 110
Not applicableApproved For MarketingNCT03825484
What this trial is testing

Expanded Access Program (EAP) for Participants With Advanced Cancers and Fibroblast Growth Factor Receptor (FGFR) Genetic Alterations Who Have Exhausted All Treatment Options

Who this might be right for
Advanced Cancers and FGFR Genetic Alterations
Janssen Scientific Affairs, LLC
Testing effectiveness (Phase 2)Ended earlyNCT02150967
What this trial is testing

A Phase II, Single Arm Study of BGJ398 in Patients With Advanced Cholangiocarcinoma

Who this might be right for
Advanced CholangiocarcinomaFGFR2 Gene Mutation
QED Therapeutics, a BridgeBio company 143
Early research (Phase 1)Ended earlyNCT02608125
What this trial is testing

A Dose Escalation Study in Solid Tumors and a Dose Expansion Study of PRN1371 in Adult Patients With Metastatic Urothelial Carcinoma

Who this might be right for
Solid TumorsMetastatic Urothelial Carcinoma & Renal Pelvis & Ureter
Principia Biopharma, a Sanofi Company 45
Testing effectiveness (Phase 2)Active Not RecruitingNCT03210714
What this trial is testing

Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)

Who this might be right for
Advanced Malignant Solid NeoplasmRecurrent Childhood EpendymomaRecurrent Childhood Malignant Germ Cell Tumor+29 more
National Cancer Institute (NCI) 20
Testing effectiveness (Phase 2)Study completedNCT04233567
What this trial is testing

Infigratinib for the Treatment of Advanced or Metastatic Solid Tumors in Patients With FGFR Gene Mutations

Who this might be right for
Advanced Malignant Solid NeoplasmCholangiocarcinomaMetastatic Malignant Solid Neoplasm+1 more
Sameek Roychowdhury 17